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Introduction
Alzheimer's disease (AD) is characterized clinically by progressive cognitive decline and neuropathologically by progressive neuronal loss and the accumulation of amyloid plaques and neurofibrillary tangles. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are the pathogenic cause of autosomal dominant AD (ADAD). Rare recessive mutations in APP (A673V and E693) also cause early onset AD (1) (2) (3) .
While more than 200 pathogenic mutations have been identified in APP, PSEN1, or PSEN2, more than 90 additional variants have been identified where the pathogenicity remains in question (reviewed in (4, 5) ). The uncertainty in pathogenicity may be due to several reasons.
In some cases, variants in APP, PSEN1 or PSEN2 have been identified in families with several generations of AD. In these cases, pathogenicity can be evaluated by segregation analysis: the presence of the variant in multiple individuals with clinically or pathologically confirmed AD and the absence of the variant in healthy, older family members. However, in many cases only the single proband has DNA available. Alternatively, there may be limited or no family history.
Challenges also arise when young, healthy individuals are found to be variant carriers. To assess the pathogenicity of novel variants in APP, PSEN1, and PSEN2 when pedigree and clinical data is limited or incomplete, Guerreiro and colleagues (6) proposed a pathogenicity algorithm. We have since modified and expanded this algorithm to evaluate pathogenicity of six novel variants identified through the Dominantly Inherited Alzheimer Network Extended Registry (DIAN-EXR) using genetic, biochemical, biomarker, and clinical data (7) . In our modified algorithm, we found that biochemical evidence of a change in A was informative in assessing pathogenicity where genetic data was limited (7) .
To date, more than 90 variants of unknown significance are included in genetic databases for Alzheimer's disease (AD/FTD database and AlzForum Mutations database), in part due to the reliance on genetic information alone for classification of pathogenicity (5) . Here,
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Material and Methods

Identification of Variants of Unknown Significance
To identify variants of unknown significance, we queried the AD/FTD ((5)http://www.molgen.ua.ac.be/ADMutations/) and AlzForum Mutations Databases (https://www.alzforum.org/mutations). Variants classified by the Guerreiro et al. algorithm (6) as being "not pathogenic" or "pathogenic nature unclear" were selected for evaluation by bioinformatic and in vitro analyses (n=90; Supplemental Table 1 ).
Bioinformatics
To determine whether APP, PSEN1, and PSEN2 variants represented rare or common polymorphisms, we investigated two population-based exome sequencing databases: Exome Variant Server (EVS) and Exome Aggregation Consortium (ExAC) browser. The Genome Aggregation Database (gnomAD) was excluded from this study given that sequencing data from the Alzheimer's Disease Sequencing Project are included in the database and thus would not be representative of a control population. Polymorphism phenotype v2 (PolyPhen-2; (8)) and
Sorting Intolerant From Tolerant (SIFT) were used to predict whether the amino acid change would be disruptive to the encoded protein.
In Vitro Analyses
Plasmids and mutagenesis
The full-length APP cDNA (isoform 695) was cloned into pcDNA3.1 (9) . APP variants J o u r n a l P r e -p r o o f Journal Pre-proof (Table 1) were introduced into the APP cDNA using a QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). Clones were sequenced to confirm the presence of the variant and the absence of additional modifications. APP wild-type (WT) and pathogenic APP KM670/671NL, APP L723P and APP K724N mutations were included as controls. Three variants were not generated due to incompatibility with the cDNA plasmid: APP E296K, APP P299L, APP IVS17 83-88delAAGTAT, APP c *18 C>T, and APP c *372 A>G (N/A; Table 1 ).
The full-length PSEN1 cDNA was cloned into pcDNA3.1 myc/his vector (10) . PSEN1 variants ( Table 1) were introduced into the PSEN1 cDNA and screened as described above.
PSEN1 WT and pathogenic PSEN1 A79V, PSEN1 L286V, and PSEN1 exon 9 deletion (E9) mutations were included as controls. One variant was not generated due to incompatibility with the cDNA plasmid: PSEN1 N32N. Four additional variants failed at the mutagenesis step and were not modeled in the cellular assay: PSEN1 L219R, PSEN1 D333G, PSEN1 T354I, and PSEN1 S365Y (N/A; Table 1 ).
The full-length PSEN2 cDNA was cloned into pcDNA3.1 vector (11) . PSEN2 variants (Table 1) were introduced into the PSEN2 cDNA and screened as described above. PSEN2 WT and the pathogenic PSEN2 N141I mutation were included as controls (12) . Nine variants failed at the mutagenesis step and were not modeled in the cellular assay: PSEN2 T18M, PSEN2 R29H, PSEN2 V101M, PSEN2 S130L, PSEN2 H162N, PSEN1 V214L, PSEN2 T301M, PSEN2 K306fs, and PSEN2 P334R (N/A; Table 1 ).
In total, we generated 65 plasmids containing VUS in APP, PSEN1 or PSEN2.
Transient transfection
To assess APP variants, we transiently expressed APP WT, variant, or mutant APP in mouse neuroblastoma cells (N2A). To assess PSEN1 and PSEN2 variants, we used mouse neuroblastoma cells in which endogenous Psen1 and Psen2 were knocked out by L143H, PSEN2 A237V and PSEN2 A377V (N/A; Table 1 ).
A Enzyme-linked immunosorbent assay (ELISA)
Conditioned media was collected and centrifuged at 3000xg at 4°C for 10 minutes to remove cell debris. Levels of A40 and A42 in cell culture media were measured by sandwich ELISA as directed by the manufacturer (Life Technologies, Carlsbad, CA, USA). Statistical difference was measured using a one-way ANOVA and post-hoc Dunnett test.
Immunoblots were probed with 22C11 (1:1000; Millipore) and goat-anti-rabbit-HRP (1:5000; Thermo Fisher).
Results and Discussion
The impact of variants of unknown significance in APP, PSEN1 and PSEN2 on A levels in vitro.
Prior cellular studies have largely focused on defining the impact of known pathogenic mutations in APP, PSEN1, and PSEN2 on extracellular A40 and A42 levels (14-16). Many common and rare variants occur within APP, PSEN1, and PSEN2 that may be risk factors, protective factors, or benign, non-pathogenic polymorphisms (17, 18) . Yet, to date, no single study has systematically examined the impact of these variants of unknown significance on Aβ isoform levels in vitro. The goal of this study was to determine the extent to which variants in APP, PSEN1 and PSEN2 impact Aβ isoform levels and to determine the utility of our assay to discriminate between pathogenic and non-pathogenic variants.
We compared extracellular Aβ40, Aβ42, and Aβ42/40 in the media of mouse N2A cells expressing APP WT, pathogenic APP mutations (KM670/671NL, L723P or K724N) or APP containing one of 22 variants of unknown significance ( Figure 1 ). We found that four of the 22 APP variants resulted in a significant increase in the Aβ42/40 ratio compared with APP WT: APP S614G, APP P620A, APP A713T, and APP T719N (Figure 1 ; Supplemental Table 2 ). APP T719N was a variant of unknown significance that has recently been classified as pathogenic (7) . Consistent with the reported effects of APP KM670/671NL, we found that one APP variant (APP P620L) produced a significant increase in Aβ40 and Aβ42 without altering the Aβ42/40 ratio ( Figure 1C ; Supplemental Table 2 ). Two APP variants resulted in a significant increase in Aβ42 without significantly altering the Aβ42/40 ratio: APP G708G and APP H733P ( Table 2 ). Those variants that significantly increased the Aβ42/40 ratio or Aβ40 and Aβ42 occur in the juxtamembrane region or amyloid beta domain consistent with known pathogenic mutations; however, some variants, including APP S614G, APP P620L, and APP P620A, occur outside of the regions that are routinely sequenced ( Figure 1A ) (5) .
To evaluate variants of unknown significance in PSEN1 and PSEN2, we selected a cell line in which APP is metabolized similarly to neuronal cells and in which endogenous presenilin genes are absent in order to avoid background Aβ production: N2A-PS1/PS2 KO. The absence of endogenous Psen1 and Psen2 allows us to capture effects of known pathogenic mutations in these genes, where a robust reduction in Aβ40 results in a shift in the Aβ42/40 ratio. We evaluated 19 variants in PSEN1 and 22 variants in PSEN2 (Figures 2 and 3) . Aβ40, Aβ42, and Aβ42/40 levels were compared to PSEN1 WT or PSEN2 WT, respectively. Six of the 19 PSEN1 variants resulted in a significant increase in the Aβ42/40 ratio: PSEN1 M84V, PSEN1 T99A, PSEN1 QR127G, PSEN1 H131R, PSEN1 M146V, and PSEN1 G378fs (Figure 2 ; Supplemental   Table 2 ). Six variants resulted in a significant increase in Aβ40 and Aβ42 or Aβ42 only compared with PSEN1 WT: PSEN1 D40∆, PSEN1 E69D, PSEN1 R108Q, PSEN1 R358Q, PSEN1 A396T, and PSEN1 I439V (Figure 2 ; Supplemental Table 2 ). We found that six of 22 PSEN2 variants resulted in a significant increase in the Aβ42/40 ratio: PSEN2 P123L, PSEN2 I235F, PSEN2 L238F, PSEN2 R284G, PSEN2 P348L, and PSEN2 D439A (Figure 3 ; Supplemental Table 2 ). We evaluated several known polymorphisms in PSEN2 that do not cause AD: PSEN2 R62H and PSEN2 R71W (12) . Cells expressing these benign variants failed to produce a significant change in Aβ40 or Aβ42 (Figure 3 ). Overall, variants of unknown significance in PSEN1 and PSEN2 that alter Aβ were located across the gene. Thus, leveraging multiple types of data (genetic, bioinformatic, and cellular) can be most informative in evaluating variants of unknown significance.
While the pathogenicity algorithm is designed to discriminate between pathogenic and non-pathogenic variants, by utilizing the in vitro assay, we have the opportunity to discriminate J o u r n a l P r e -p r o o f Journal Pre-proof between benign, non-pathogenic variants and those that may confer resilience to AD. A rare variant in APP, APP A673T, has been reported to confer protection against AD risk (19, 20) . In vitro, APP A673T results in a significant reduction of Aβ42 and Aβ40 without altering total APP levels by decreasing BACE activity (20) . Interestingly, we observed that eight variants in APP, PSEN1, and PSEN2 produced significantly lower levels of Aβ42 and Aβ40 (Figures 1-3 ;
Supplemental Table 2 ) without altering total APP levels: APP A235V; APP Y538H; APP V713V; PSEN1 V191A; PSEN1 G378fs; PSEN2 E126fs; PSEN2 A252T; PSEN2 V393M ( Figure 4 ).
Thus, we propose that these variants may reduce Aβ production and confer resilience to AD.
Pathogenicity
Evaluating pathogenicity of variants of unknown significance requires carefully weighing the clinical phenotype of the variant carrier along with bioinformatic predictions and functional analyses. By evaluating more than 90 variants of unknown significance in vitro, we found that only a subset of variants were able to significantly alter Aβ40, Aβ42, or Aβ42/40 in a manner consistent with known pathogenic mutations. Thus, we propose that the impact of variants on extracellular Aβ levels in vitro should be weighed separately in the pathogenicity algorithm. As such, we have revised the pathogenicity algorithm for use when segregation data is unavailable ( Figure 5 ).
Applying this modified pathogenicity algorithm to the 90 variants of unknown significance, we classified 19 variants as probably pathogenic (APP P620A; APP P620L; APP H733P; PSEN1 E69D; PSEN1 M84V; PSEN1 T99A; PSEN1 R108Q; PSEN1 QR127G; PSEN1 H131R; PSEN1 M146V; PSEN1 R358Q; PSEN1 G378fs; PSEN1 A396T; PSEN1 I439V; PSEN2 P123L; PSEN2 I235F; PSEN2 L238F; PSEN2 R284G; PSEN2 P348L; Table 1 ). Many of the variants of unknown significance were identified in single individuals presenting clinically with AD (6, 7, 18, (21) (22) (23) (24) (25) (26) (27) . Our in vitro assay revealed that nine variants significantly reduced Aβ40 and Aβ42 levels ( Figure 1C, 2C, 3C ). Among these variants, four variants were identified in Table 1 ), while four variants were identified in individuals with no evidence of neurodegeneration (APP Y538H, APP A713V, PSEN1 V191A, PSEN2 A252T; Table 1 ). Thus, we predict that these five variants confer resilience to AD.
Conclusions
Here, we applied genetic, bioinformatic, and functional data to an algorithm to assess pathogenicity of variants of unknown significance in APP, PSEN1 and PSEN2. We propose that 19 variants are probable pathogenic AD mutations. This algorithm was adapted and modified from a pathogenicity algorithm originally proposed by Guerreiro and colleagues (6) to impute pathogenicity when extensive genetic data is missing. We have expanded upon this algorithm in several important ways: (1) expanding the number of controls in the association analyses from 100 to 65,000 by leveraging the EVS and ExAC databases; (2) incorporating cell-based assays to evaluate the impact of novel variants on A levels; and (3) evaluating the bioinformatic functional findings (e.g. conservation between PSEN1 and PSEN2 and the presence of other mutations at the same residue) independent of the cell-based functional findings. The cell-based assay focused on the impact of variants on A42 and A40 levels. Some pathogenic mutations have been reported to lead to reduced A40 and elevated A43 and A42 (28). In many of these mutations, the increase in A43 is much greater than A42 (28). Because our assays focus on A42 and A40, we may not capture the magnitude of the aberrant effect on A levels.
Ultimately, definitive pathogenicity comes from segregation: presence of the variant in multiple family members with autopsy confirmed AD and absence in family members free of disease.
Designation of a variant as pathogenic will allow for individuals to enroll in observational studies
and clinical trials for AD, with clear applications in clinical and research settings. 
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